N/A
Completed N=35
Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)
Replacement Therapy, Renal
Source: ClinicalTrials.gov NCT02287493 ↗
Enrolled (actual)
35
Serious AEs
—
Results posted
Feb 2021
Primary outcomePrimary: Patients Showing Serum Levels of Meropenem or Ceftazidim at the End of SLED Above the Minimal Inhibitory Concentration (MIC) — 0; 0; 19; 16 Participants
Summary
In a prospective, non-interventional, monocentric observational study the pharmacokinetic properties of selected antiinfective drugs during sustained low-efficiency dialysis (SLED) will be analyzed.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patients Showing Serum Levels of Meropenem or Ceftazidim at the End of SLED Above the Minimal Inhibitory Concentration (MIC) |
0; 0; 19; 16 | — |
| SECONDARY Mortality |
9; 9 | — |
| SECONDARY Length of Stay (LOS) |
56; 90; 36; 67 | — |
| SECONDARY Number of Patients With Clinical Cure of Infections |
10; 9 | — |
Eligibility Criteria
Inclusion Criteria
- age: 18 or older
- patients receiving SLED and either meropenem or ceftazidim
Exclusion Criteria
- missing informed consent
Data sourced from ClinicalTrials.gov (NCT02287493). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.